Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Protocol ID
AAML1831
Disease (Sub Disease)
Acute Myeloid Leukemia
Diagnosis Stage
Newly diagnosed
Sponsor
Children's Oncology Group
Links
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 21 Years
International registry ID's
NCT04293562
| Study Title | A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations |
|---|---|
| Protocol ID | AAML1831 |
| Disease (Sub Disease) | Acute Myeloid Leukemia |
| Diagnosis Stage | Newly diagnosed |
| Sponsor | Children's Oncology Group/ |
| Links | https://clinicaltrials.gov/study/NCT04293562 |
| Trial Status | Preparing to Open |
| Trial Open Date | 21/07/2020 |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 21 Years |
| International registry ID's | NCT04293562 |